Clinical Efficacy of Capecitabine and Cyclophosphamide (XC) in Patients with Metastatic Breast Cancer

被引:0
作者
Shien, Tadahiko [1 ]
Doihara, Hiroyoshi [1 ]
Nishiyama, Keiko [1 ]
Masuda, Hiroko [1 ]
Nogami, Tomohiro [1 ]
Ikeda, Hirokuni [1 ]
Taira, Naruto [1 ]
机构
[1] Okayama Univ Hosp, Dept Breast & Endocrine Surgoy, Okayama 7008558, Japan
关键词
metastatic breast cancer; metronomic; chemotherapy; THYMIDINE PHOSPHORYLASE EXPRESSION; ANTHRACYCLINE-PRETREATED PATIENTS; PHASE-II TRIAL; COMBINATION THERAPY; METRONOMIC CYCLOPHOSPHAMIDE; PLUS DOCETAXEL; MULTICENTER; PACLITAXEL; 5'-DEOXY-5-FLUOROURIDINE; CHEMOTHERAPY;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Combined low-dose therapy of oral capecitabine (Xeloda) and cyclophosphamide (XC) has been demonstrated to be useful for long-term control of lesions in patients with metastatic breast cancer (MBC) and is aimed at symptomatic alleviation and prolongation of survival. Here, a retrospective review was conducted of MBC patients administered XC at the Okayama University Hospital (OUH), to evaluate responses to XC, adverse events and time to progression (TTP). Twenty patients with MBC received XC between 2006 and 2009. With the exception of 2 elderly patients who were over the age of 70 at the initial examination, all of the patients had received prior treatment with an anthracycline and/or a taxane. No complete response (CR) cases were observed, but partial response (PR) was achieved in 6 patients (30%) and SD in 9 (45%), of whom 5 (20%) sustained SD status for >= 12 months. The median TTP was 6 months (range: 3-27 mo.). Three patients developed Grade 3 adverse events (diarrhea, nausea and stomatitis), but no other patients developed adverse reactions causing interruption of the therapy. XC was safe even in previously treated and elderly MBC patients; moreover, it yielded remarkable clinical responses.
引用
收藏
页码:231 / 237
页数:7
相关论文
共 50 条
[41]   Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results [J].
Michalaki, Vasiliki ;
Gennatas, Spyridon ;
Gennatas, Konstantine .
ANTI-CANCER DRUGS, 2009, 20 (03) :204-207
[42]   Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine [J].
Ningning Dong ;
Jing Yu ;
Chaoying Wang ;
Xiaohui Zheng ;
Zheng Wang ;
Lijun Di ;
Guohong Song ;
Budong Zhu ;
Li Che ;
Jun Jia ;
Hanfang Jiang ;
Xinna Zhou ;
Xiaoli Wang ;
Jun Ren .
Journal of Cancer Research and Clinical Oncology, 2012, 138 :1197-1203
[43]   Acceptable but Limited Efficacy of Capecitabine-Based Doublets in the First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Pilot Study [J].
Liao, Yuqian ;
Fan, Ying ;
Wan, Yiye ;
Li, Jun ;
Peng, Lixiang .
CHEMOTHERAPY, 2013, 59 (03) :207-213
[44]   The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer [J].
Chila, Giovanna ;
Guarini, Vincenzo ;
Galizia, Danilo ;
Geuna, Elena ;
Montemurro, Filippo .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 :2711-2720
[45]   Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial [J].
Xu, B. ;
Sun, T. ;
Zhang, Q. ;
Zhang, P. ;
Yuan, Z. ;
Jiang, Z. ;
Wang, X. ;
Cui, S. ;
Teng, Y. ;
Hu, X-C ;
Yang, J. ;
Pan, H. ;
Tong, Z. ;
Li, H. ;
Yao, Q. ;
Wang, Y. ;
Yin, Y. ;
Sun, P. ;
Zheng, H. ;
Cheng, J. ;
Lu, J. ;
Zhang, B. ;
Geng, C. ;
Liu, J. ;
Shen, K. ;
Yu, S. ;
Tang, L. ;
Qiu, R. .
ANNALS OF ONCOLOGY, 2021, 32 (02) :218-228
[46]   Retrospective Analysis of Capecitabine Monotherapy in Patients with Metastatic Breast Cancer: A Single Center Experience [J].
Kurt, Mevluet ;
Aksoy, Sercan ;
Hayran, Mutlu ;
Gullu, Ibrahim ;
Guler, Niluefer .
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2009, 19 (01) :9-17
[47]   Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane [J].
Park, Ji Soo ;
Jeung, Hei-Cheul ;
Rha, Sun Young ;
Ahn, Joong Bae ;
Kang, Beodeul ;
Chon, Hong Jae ;
Hong, Min Hee ;
Lim, Seungtaek ;
Yang, Woo Ick ;
Nam, Chung Mo ;
Chung, Hyun Cheol .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (04) :799-808
[48]   Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer [J].
Crown, John P. ;
Dieras, Veronique ;
Staroslawska, Elzbieta ;
Yardley, Denise A. ;
Bachelot, Thomas ;
Davidson, Neville ;
Wildiers, Hans ;
Fasching, Peter A. ;
Capitain, Olivier ;
Ramos, Manuel ;
Greil, Richard ;
Cognetti, Francesco ;
Fountzilas, George ;
Blasinska-Morawiec, Maria ;
Liedtke, Cornelia ;
Kreienberg, Rolf ;
Miller, Wilson H., Jr. ;
Tassell, Vanessa ;
Huang, Xin ;
Paolini, Jolanda ;
Kern, Kenneth A. ;
Romieu, Gilles .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) :2870-+
[49]   Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer [J].
Blum, Joanne L. ;
Barrios, Carlos H. ;
Feldman, Nancy ;
Verma, Sunil ;
McKenna, Edward F. ;
Lee, Luen F. ;
Scotto, Nana ;
Gralow, Julie .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) :777-788
[50]   Clinical Efficacy of Bevacizumab in Conjunction with Oxaliplatin and Capecitabine in Managing Metastatic Colorectal Cancer [J].
Zang, J. ;
Zhang, X. ;
Wang, Qing ;
Gan, Jianchen .
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 85 :290-294